Stockscreener 앱 받기
1.77
1.67%
-0.03
전일 마감가:
$1.80
열려 있는:
$1.81
하루 거래량:
18,787
Relative Volume:
1.86
시가총액:
$20.77M
수익:
-
순이익/손실:
$-3.15M
주가수익비율:
-5.7995
EPS:
-0.3052
순현금흐름:
$-2.23M
1주 성능:
-1.67%
1개월 성능:
-19.91%
6개월 성능:
-33.21%
1년 성능:
+7.93%
1일 변동 폭
$1.76
$1.83
1주일 범위
$1.76
$1.8784
52주 변동 폭
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
GDTC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
1.77 | 20.77M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomed Therapeutics Ltd 주식(GDTC)의 최신 뉴스
Is CytoMed Therapeutics Limited a candidate for recovery playRisk Aware Trading Ideas with Alert Levels - Newser
Real time scanner hits for CytoMed Therapeutics Limited explainedDaily Technical Forecast for Quick Gains - Newser
CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 3.7% – Here’s What Happened - Defense World
Comparing CytoMed Therapeutics Limited in custom built stock radarsAI Pattern Recognition and Trade Prediction - Newser
How high can CytoMed Therapeutics Limited stock price go in 2025Buy and Hold Strategy for Capital Safety - Newser
CytoMed Therapeutics Limited stock trendline breakdownMonthly Long-Term Market Recap and Summary - Newser
Is it time to cut losses on CytoMed Therapeutics LimitedFree Momentum Based Equity Trading Plan - Newser
Is CytoMed Therapeutics Limited Stock Overbought or Oversold RSI Indicator AnalysisAlgorithmic Prediction of Market Breakouts - Newser
Published on: 2025-07-29 02:23:22 - metal.it
Does CytoMed Therapeutics Limited stock perform well during market downturnsCapitalize on trading strategies that deliver - Jammu Links News
What is the risk reward ratio of investing in CytoMed Therapeutics Limited stockUnrivaled growth potential - Jammu Links News
Price momentum metrics for CytoMed Therapeutics Limited explainedTechnical Trade Plan with Entry Checklist - Newser
What are analysts’ price targets for CytoMed Therapeutics Limited in the next 12 monthsCapitalize on fast-moving stock opportunities - Jammu Links News
CytoMed Therapeutics Limited Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
What drives CytoMed Therapeutics Limited stock priceExplosive market performance - jammulinksnews.com
Is CytoMed Therapeutics Limited a good long term investmentRapid-fire capital growth - jammulinksnews.com
What drives SDST stock priceConsistently profitable trades - Autocar Professional
The ANGELICA Trial and the Future of Allogeneic CAR-T: A Strategic Investment Perspective - AInvest
CytoMed's Breakthrough Cancer Cell Therapy Shows Promise in Phase 1 Trial, Advances to Higher Dose Testing - Stock Titan
GDTC advances CTM-N2D: Dose Level 1 complete, Phase I escalates | GDTC SEC FilingForm 6-K - Stock Titan
COST Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
Blue Chip Stocks High Precision Stock TipsBreakthrough stock performance - jammulinksnews.com
What analysts say about CytoMed Therapeutics Limited stockExceptional profit velocity - jammulinksnews.com
How CytoMed Therapeutics Limited stock performs during market volatilitySmart Money Trade Setups - Newser
What makes CytoMed Therapeutics Limited stock price move sharplySafe and Scalable Investment Tips - Newser
Why CytoMed Therapeutics Limited stock attracts strong analyst attentionTrade With Low Risk Exposure - Newser
CytoMed Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
CytoMed Therapeutics shareholders approve all proposals at annual meeting - Investing.com
The Pipeline for of iPSC-Derived Cell Therapeutics in 2025 - BioInformant
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shel - GuruFocus
CytoMed Therapeutics Files $50 Million Mixed Shelf - MarketScreener
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shelf Offering | GDTC Stock News - GuruFocus
CytoMed Therapeutics schedules annual shareholder meeting - Investing.com Australia
CytoMed Therapeutics schedules annual shareholder meeting By Investing.com - Investing.com India
CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.4% – Here’s Why - Defense World
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
Cytomed Therapeutics Ltd shares rise 3.08% intraday after Osteopore secures EU approval for custom orthopaedic and cranial implants. - AInvest
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight - The Globe and Mail
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com
Cytomed Therapeutics Ltd (GDTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.91%
3.06%
자본화:
|
볼륨(24시간):